    Rogerio Vivaldi | Bioverativ Inc. | ZoomInfo.com










 





Insider Trading - Vivaldi Coelho Rogerio - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Vivaldi Coelho Rogerio





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Common stock purchase or sale:



TransactionDate
ReportedDate
Company
Symbol
InsiderRelationship
SharesTraded
AveragePrice
TotalAmount
SharesOwned
Filing




2016-07-15Sale
2016-07-194:23 pm
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
7,000
$53.03
$371,224
155,186(Direct)
View


2016-04-20Sale
2016-04-224:07 pm
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
7,000
$40.02
$280,140
160,386(Direct)
View


2015-10-13Sale
2015-10-147:32 pm
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
24,000
$48.15
$1,155,600
165,186(Direct)
View


2015-10-07Sale
2015-10-097:21 pm
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
41,000
$48.85
$2,002,800
202,519(Direct)
View


2015-02-04Purchase
2015-02-064:48 pm
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
2,500
$23
$57,500
6,383(Direct)
View




Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2016-07-15Exercise
2016-07-194:23 pm
N/AN/A
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
1,000
$3.45
155,186(Direct)
View


2016-07-15Exercise
2016-07-194:23 pm
N/AN/A
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
1,000
$3.45
155,186(Direct)
View


2016-07-15Exercise
2016-07-194:23 pm
N/AN/A
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
5,000
$7.5
155,186(Direct)
View


2016-07-15Exercise
2016-07-194:23 pm
N/A2024-06-10
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
1,000
$3.45
155,186(Direct)
View


2016-07-15Exercise
2016-07-194:23 pm
N/A2024-08-11
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
1,000
$3.45
155,186(Direct)
View


2016-07-15Exercise
2016-07-194:23 pm
N/A2024-12-01
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
5,000
$7.5
155,186(Direct)
View


2016-04-20Exercise
2016-04-224:07 pm
N/AN/A
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
1,000
$3.45
160,386(Direct)
View


2016-04-20Exercise
2016-04-224:07 pm
N/AN/A
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
4,800
$7.5
160,386(Direct)
View


2016-04-20Exercise
2016-04-224:07 pm
N/AN/A
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
1,000
$3.45
160,386(Direct)
View


2016-04-20Exercise
2016-04-224:07 pm
N/AN/A
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
200
$7.5
160,386(Direct)
View


2016-04-20Exercise
2016-04-224:07 pm
N/A2024-08-11
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
1,000
$3.45
160,386(Direct)
View


2016-04-20Exercise
2016-04-224:07 pm
N/A2024-12-01
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
4,800
$7.5
160,386(Direct)
View


2016-04-20Exercise
2016-04-224:07 pm
N/A2024-06-10
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
1,000
$3.45
160,386(Direct)
View


2016-04-20Exercise
2016-04-224:07 pm
N/A2024-12-01
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
200
$7.5
160,386(Direct)
View


2016-01-05Option Award
2016-01-077:00 pm
N/A2026-01-04
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
55,000
$40.44
55,000(Direct)
View


2015-10-13Exercise
2015-10-147:32 pm
N/AN/A
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
37,333
$7.5
165,186(Direct)
View


2015-10-13Exercise
2015-10-147:32 pm
N/A2024-12-01
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
37,333
$7.5
165,186(Direct)
View


2015-10-07Exercise
2015-10-097:21 pm
N/AN/A
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
10,000
$3.45
202,519(Direct)
View


2015-10-07Exercise
2015-10-097:21 pm
N/AN/A
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
30,000
$7.5
202,519(Direct)
View


2015-10-07Exercise
2015-10-097:21 pm
N/A2024-06-10
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
5,000
$3.45
202,519(Direct)
View


2015-10-07Exercise
2015-10-097:21 pm
N/A2024-08-11
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
5,000
$3.45
202,519(Direct)
View


2015-10-07Exercise
2015-10-097:21 pm
N/A2024-12-01
Spark Therapeutics Inc.
ONCE
Vivaldi Coelho RogerioChief Commercial Officer
30,000
$7.5
202,519(Direct)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Fri, 28 Jul 2017 23:48:02 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  











NERV Rogério Vivaldi Coelho Insider Trades for Minerva Neurosciences Inc.


































Bulletin






Investor Alert





















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Minerva Neurosciences Inc.

                  NASDAQ: NERV
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Minerva Neurosciences Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 28, 2017, 4:30 p.m.


NERV

/quotes/zigman/32481619/composite


$
6.60




Change

0.00
0.00%

Volume
Volume 1,348
Quotes are delayed by 20 min








/quotes/zigman/32481619/composite
Previous close

$
			6.75
		


$
				6.60
			
Change

-0.15
-2.22%





Day low
Day high
$6.50
$6.90










52 week low
52 week high

            $6.50
        

            $14.92
        


















Insider Activity


Individual




Rogério Vivaldi Coelho






Transactions


Date
Shares
Transaction
Value





07/01/2014
41,667


 
Acquisition at $6 per share.


250,002





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Dr. Rémy  Luthringer 
President, Chief Executive Officer & Director




Mr. Joseph  Reilly 
Chief Operating Officer & Senior Vice President




Mr. Geoffrey  Race 
Executive VP, Chief Financial & Business Officer




Dr. Michael  Davidson 
Chief Medical Officer




Mr. Frederick W. Ahlholm 
Chief Accounting Officer & Senior Vice President




Mr. William B. Boni 
VP-Investor Relations & Corporate Communications




Mr. Mark S. Levine 
Secretary, Senior Vice President & General Counsel




Mr. Marc D. Beer 
Chairman




Dr. Thode Fouzia Laghrissi 
Independent Director




Dr. Francesco  de Rubertis 
Independent Director




Dr. David J. Kupfer 
Independent Director




Mr. Jan G. van Heek 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




12:48 AM EDT
July 29, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
12:34aBREAKINGElon Musk details Tesla Model 3 pricing, range
12:21aTesla: Standard Model 3 will cost $35,000, long-range model will cost $44,000
9:16pWall Street isn’t ready for a 1,100-point tumble in the Dow industrials
7:39pBarron's Buzz: Robo 2.0, Facebook and Twitter, Trading On News
7:29pA Wild Week in Washington 
6:32pThe dark side of cruises
6:32pThe highest paid athletes in the world, in one chart
6:31pO.J. Simpson made over $400,000 while in prison and won’t have to give any of it to the Goldman family
6:31p Trump to Police: 'Don't Be Too Nice'
6:31pHere are 10 co-workers you should avoid like the plague — especially in meetings
6:29pTop 10 most annoying people you may want to unfriend on Facebook 
6:29pThis is one person you should never unfriend on Facebook...
6:29p3 horrible ways typos could alter the course of your life
6:27pPaint your bathroom this color and boost your home’s selling price by $5,400
6:27pAmericans’ new badge of honor: ‘I was blocked by a celebrity!’
6:27p5 weird things I found out about America in my first 24 hours 
6:14pBeyond Tesla: 7 stocks driving the autonomous car revolution
6:14pThese 7 highly taxed companies need Congress to finally act on tax reform
6:11pWatch out: ‘Kids’ are making the most money in this stock market 
6:10p7 real ways for millennials to save money (not by brownbagging and skipping Starbucks)
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,830.31

+33.76
+0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,374.68

-7.51
-0.12%





s&p 500

/quotes/zigman/3870025/realtime
2,472.10

-3.32
-0.13%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15

























































ONCE Rogério Vivaldi Coelho Insider Trades for Spark Therapeutics Inc.


































Bulletin






Investor Alert





















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Spark Therapeutics Inc.

                  NASDAQ: ONCE
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Spark Therapeutics Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 28, 2017, 4:29 p.m.


ONCE

/quotes/zigman/44238715/composite


$
71.33




Change

0.00
0.00%

Volume
Volume 7,166
Quotes are delayed by 20 min








/quotes/zigman/44238715/composite
Previous close

$
			70.29
		


$
				71.33
			
Change

+1.04
+1.48%





Day low
Day high
$69.36
$71.74










52 week low
52 week high

            $35.07
        

            $74.29
        


















Insider Activity


Individual




Rogério Vivaldi Coelho



Dr. Rogério Vivaldi Coelho, MD MBA, is Chief Commercial Officer at Spark Therapeutics, Inc.
Dr. Vivaldi Coelho was previously employed as Chief Executive Officer & Director by Minerva Neurosciences, Inc. and Senior Vice President & Head-Rare Diseases by Genzyme Corp. He also served on the board at Mind-NRG SA.
He received his MBA from the COPPEAD Graduate School of Business and a doctorate degree from the Federal University of Rio de Janeiro.



Transactions


Date
Shares
Transaction
Value





07/15/2016
1,400


 
Disposition at $53.32 per share.


74,648


07/15/2016
5,600


 
Disposition at $52.96 per share.


296,576


07/15/2016
5,000


 
Derivative/Non-derivative trans. at $7.5 per share.


37,500


07/15/2016
1,000


 
Derivative/Non-derivative trans. at $3.45 per share.


3,450


07/15/2016
1,000


 
Derivative/Non-derivative trans. at $3.45 per share.


3,450


04/21/2016
1,200


 
Disposition at $40.02 per share.


48,024


04/21/2016
200


 
Derivative/Non-derivative trans. at $7.5 per share.


1,500


04/21/2016
1,000


 
Derivative/Non-derivative trans. at $3.45 per share.


3,450


04/20/2016
5,800


 
Disposition at $40.02 per share.


232,116


04/20/2016
4,800


 
Derivative/Non-derivative trans. at $7.5 per share.


36,000


04/20/2016
1,000


 
Derivative/Non-derivative trans. at $3.45 per share.


3,450


10/13/2015
24,000


 
Disposition at $48.15 per share.


1,155,600


10/13/2015
37,333


 
Derivative/Non-derivative trans. at $7.5 per share.


279,997


10/07/2015
1,000


 
Disposition at $50.4 per share.


50,400


10/07/2015
40,000


 
Disposition at $48.81 per share.


1,952,400


10/07/2015
30,000


 
Derivative/Non-derivative trans. at $7.5 per share.


225,000


10/07/2015
10,000


 
Derivative/Non-derivative trans. at $3.45 per share.


34,500


02/04/2015
2,500


 
Acquisition at $23 per share.


57,500





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Jeffrey D. Marrazzo 
Chief Executive Officer & Director




Mr. John  Furey 
Chief Operating Officer




Mr. Stephen W. Webster 
CFO & Principal Accounting Officer




Dr. J. Fraser Wright 
Chief Technology Officer




Mr. Daniel R. Faga 
Chief Business Officer




Dr. Steven M. Altschuler 
Chairman




Ms. Lota S. Zoth 
Independent Non-Executive Director




Dr. Anand  Mehra 
Independent Director




Dr. Lars G. Ekman 
Independent Director




Dr. Charles Elliott Sigal 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




12:48 AM EDT
July 29, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
12:34aBREAKINGElon Musk details Tesla Model 3 pricing, range
12:21aTesla: Standard Model 3 will cost $35,000, long-range model will cost $44,000
9:16pWall Street isn’t ready for a 1,100-point tumble in the Dow industrials
7:39pBarron's Buzz: Robo 2.0, Facebook and Twitter, Trading On News
7:29pA Wild Week in Washington 
6:32pThe dark side of cruises
6:32pThe highest paid athletes in the world, in one chart
6:31pO.J. Simpson made over $400,000 while in prison and won’t have to give any of it to the Goldman family
6:31p Trump to Police: 'Don't Be Too Nice'
6:31pHere are 10 co-workers you should avoid like the plague — especially in meetings
6:29pTop 10 most annoying people you may want to unfriend on Facebook 
6:29pThis is one person you should never unfriend on Facebook...
6:29p3 horrible ways typos could alter the course of your life
6:27pPaint your bathroom this color and boost your home’s selling price by $5,400
6:27pAmericans’ new badge of honor: ‘I was blocked by a celebrity!’
6:27p5 weird things I found out about America in my first 24 hours 
6:14pBeyond Tesla: 7 stocks driving the autonomous car revolution
6:14pThese 7 highly taxed companies need Congress to finally act on tax reform
6:11pWatch out: ‘Kids’ are making the most money in this stock market 
6:10p7 real ways for millennials to save money (not by brownbagging and skipping Starbucks)
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,830.31

+33.76
+0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,374.68

-7.51
-0.12%





s&p 500

/quotes/zigman/3870025/realtime
2,472.10

-3.32
-0.13%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15
























































Rogerio Coelho Vivaldi M.D., MBA: Executive Profile & Biography - Bloomberg









































  





















































































July 29, 2017 12:48 AM ET
Biotechnology

Company Overview of Bioverativ Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Rogerio Coelho Vivaldi M.D., MBAChief Global Therapeutic Operations Officer and Executive Vice President, Bioverativ Inc.AgeTotal Calculated CompensationThis person is connected to 0 Board Members in 0 different organizations across 4 different industries.53$658,888As of Fiscal Year 2016
Background

		Dr. Rogerio Coelho Vivaldi, M.D., MBA has been the Chief Global Therapeutic Operations Officer and Executive Vice President of Bioverativ Inc. since October 2016. Dr. Vivaldi served as Chief Commercial Officer at Spark Therapeutics, Inc. (also known as Spark Therapeutics, LLC) from December 16, 2014 to October 28, 2016. He served as Chief Executive Officer of Minerva Neurosciences, Inc. from November 2013 to November 30, 2014. Dr. Vivaldi served as President of Minerva ... Neurosciences, Inc. since November 2013. He served as Senior Vice President and Head of Rare Diseases at Genzyme Therapeutic Products Limited Partnership from October 2011 to October 2013. Dr. Vivaldi was responsible for day-to-day management and strategic planning of Genzyme’s rare disease business worldwide. Dr. Vivaldi served as the Head of Rare Diseases of Genzyme Corporation since November 10, 2011. Dr. Vivaldi joined Genzyme Corp. in 1995 and served as its Senior Vice President and President of Genzyme Latin America from January 2004 to June 2010. Dr. Vivaldi was the Founder and President of Genzyme do Brazil Ltda. Dr. Vivaldi served as the President and Head of the Renal and Endocrinology Businesses at Genzyme Corporation from May 2010 to November 10, 2011. Prior to 2004, Dr. Vivaldi founded Genzyme in Brazil in 1997. Dr. Vivaldi has been an Independent Director of Spark Therapeutics, LLC since April 1, 2014. He served as a Director of Minerva Neurosciences, Inc. since November 2013 until November 30, 2014. Dr. Vivaldi is an Endocrinologist by training. Dr. Vivaldi holds M.D. from Universidade do Rio de Janeiro (UNIRIO) Medical School and M.B.A. from Copead Universidade Federal do Rio de Janeiro (UFRJ).Read Full Background




Corporate Headquarters
225 Second AvenueWaltham, Massachusetts 02451United StatesPhone: 781-663-4400Fax: --
Board Members Memberships
				There is no Board Members Memberships data available.
				Education
MD Universidade Federal do Rio de Janeiro, S.A.MBA COPPEAD Graduate School of Business
Other Affiliations
Genzyme CorporationUniversidade Federal do Rio de Janeiro, S.A.COPPEAD Graduate School of BusinessSpark Therapeutics, Inc.Minerva Neurosciences, Inc.


Annual Compensation
Salary$96,154Bonus$500,000Total Annual Compensation$596,154
Stocks Options
All Other Compensation$4,879
Total Compensation
Total Annual Cash Compensation$658,888Total Short Term Compensation$596,154Other Long Term Compensation$4,879Total Calculated Compensation$658,888




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONNamePosition/CompanyCompensationWerner  Baumann Chairman of the Board of Management and Chief Executive OfficerBayer Aktiengesellschaft$2.8MLars Fruergaard Jørgensen President & CEONovo Nordisk A/S$8.7MFlemming  Ornskov M.D., MBA, MPHCEO, MD & Executive DirectorShire plc$4.3MGuido  Oelkers Chief Executive Officer and PresidentSwedish Orphan Biovitrum AB--Marvin L. White Chief Executive Officer, President and DirectorAptevo Therapeutics Inc.$461.2KCompensation as of Fiscal Year 2016.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Bioverativ Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close





























Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft











Coelho Rogerio  Vivaldi - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











Coelho Rogerio  Vivaldi
Check out list of companies and businesses related to Coelho Rogerio  Vivaldi. Find out Coelho Rogerio  Vivaldi address and contact details. View other people related to Coelho Rogerio  Vivaldi - coworkers, colleagues, companions, etc.
Address:   

C/O MINERVA NEUROSCIENCES, INC. 245 FIRST STREET SUITE 1800 CAMBRIDGE 02142 MA




Companies related to Coelho Rogerio  Vivaldi
CIKCompany NamePositionCompany Address0001598646Minerva Neurosciences, Inc.1601 TRAPELO ROAD SUITE 284 WALTHAM 024510001609351Spark Therapeutics, Inc.Chief Commercial Officer 3737 MARKET STREET SUITE 1300 PHILADELPHIA 191040001681689Bioverativ Inc.EVP, Chief Global Therapeutics 225 2ND AVENUE  WALTHAM 02451




Coelho Rogerio  Vivaldi on the Web
Persons related to Coelho Rogerio  Vivaldi - Minerva Neurosciences, Inc.NamePositionCityFrederick W  AhlholmSVP, Chief Accounting Officer WATERTOWNFrederick W  AhlholmCAMBRIDGEFrederick W  AhlholmChief Accounting Officer CAMBRIDGEMarc D  BeerDirector CAMBRIDGEMarc D  BeerDirector WALTHAMMarc D  BeerCAMBRIDGEMarc D  BeerDirector CAMBRIDGECare Capital III LLC10% Owner PRINCETONCare Capital III LLCPRINCETONCare Capital III LLC10% Owner PRINCETONCare Capital Investments III L.P.PRINCETONCare Capital Investments III L.P.PRINCETONCare Capital Investments III L.P.PRINCETONCare Capital Investments III L.P.PRINCETONCare Capital Offshore Investments III LPPRINCETONCare Capital Offshore Investments III LPPRINCETONCare Capital Offshore Investments III LPPRINCETONKupfer  DavidWalthamMichael  DavidsonChief Medical Officer WALTHAMRubertis Francesco  DeDirector LONDONRubertis Francesco  DeCAMBRIDGERubertis Francesco  DeDirector CAMBRIDGELaghrissi-Thode  FouziaWalthamDe Rubertis  FrancescoWalthamAhlholm  FredWalthamRace  GeoffWalthamIndex Venture Associates III Ltd10% Owner ST. HELIERIndex Venture Associates III Ltd10% Owner ST. HELIERIndex Venture Associates IV LtdST HELIER,JERSEY, CHANNEL ISL.Index Venture Associates V LtdST. HELIERVan Heek  JanWalthamJOHNSON & JOHNSON10% Owner NEW BRUNSWICKJOHNSON & JOHNSON DEVELOPMENT CORP ET ALNEW BRUNSWICKReilly  JosephWalthamDavid  KupferDirector WALTHAMFouzia  Laghrissi-ThodeDirector WALTHAMMark S.  LevineSVP,General Counsel & Sec. CAMBRIDGERemy  LuthringerPresident & CEO CAMBRIDGERemy  LuthringerEVP and Head of R&D CAMBRIDGEBeer  MarcWalthamLevine  MarkWalthamOllier  MicheleWalthamVandervelpen  NicoWalthamMichele  OllierDirector GENEVAMichele  OllierCAMBRIDGEMichele  OllierDirector CAMBRIDGELorenzo  PellegriniCAMBRIDGELorenzo  PellegriniDirector CAMBRIDGEGeoff  RaceEVP, CFO & CBO CAMBRIDGEGeoff  RaceEVP and CFO CAMBRIDGEJoseph H.  ReillySVP & Chief Operating Officer CAMBRIDGEJoseph H.  ReillyChief Business Officer CAMBRIDGELuthringer  RemyWalthamHEEK G JAN  VANDirector HEEK G JAN  VANDirector WALTHAMHEEK G JAN  VANCAMBRIDGEHEEK G JAN  VANDirector CAMBRIDGENico  VandervelpenDirector CAMBRIDGECoelho Rogerio  VivaldiCAMBRIDGECoelho Rogerio  VivaldiCAMBRIDGECoelho Rogerio  VivaldiPresident and CEO CAMBRIDGE(Jersey) SLP  YuccaST. HELIER(Jersey) SLP  YuccaST. HELIERPersons related to Coelho Rogerio  Vivaldi - Spark Therapeutics, Inc.NamePositionCitySRINIVAS  AKKARAJUNEW YORKSteven  AltschulerDirector EVANSVILLESteven  AltschulerPHILADELPHIAMehra  AnandPhiladelphiaDantchik  ArthurPhiladelphiaAlert Lorris  BetzDirector PHILADELPHIAHospital of Philadelphia Foundation  Children'sDirector PHILADELPHIALars  EkmanDirector BRISBANELars  EkmanPHILADELPHIASigal  ElliottPhiladelphiaDaniel  FagaChief Business Officer PHILADELPHIAJohn  FureyChief Operating Officer PHILADELPHIAJAMES  HEALYMENLO PARKKatherine A  HighSee Remarks PHILADELPHIAMarrazzo  JeffreyPhiladelphiaLa Barge  JosephPhiladelphiaBarge Joseph  LaChief Legal Officer PHILADELPHIAEkman, M.D. Ph.D.  LarsPhiladelphiaJeffrey D  MarrazzoChief Executive Officer PHILADELPHIAAnand  MehraDirector MENLO PARKAnand  MehraDirector MENLO PARKVINCENT  MILANODirector VINCENT  MILANOPHILADELPHIAMICHAEL  POWELLMENLO PARKVivaldi  RogerioPhiladelphiaELLIOT  SIGALDirector PRINCETONELLIOT  SIGALDirector PHILADELPHIASofinnova Management VIII, L.L.C.MENLO PARKSofinnova Venture Partners VIII, L.P.MENLO PARKAltschuler  StevenPhiladelphiaCoelho Rogerio  VivaldiChief Commercial Officer CAMBRIDGECoelho Rogerio  VivaldiChief Commercial Officer PHILADELPHIAStephen W  WebsterChief Financial Officer EXTONStephen W  WebsterChief Financial Officer PHILADELPHIALOTA S  ZOTHDirector GAITHERSBURGPersons related to Coelho Rogerio  Vivaldi - Bioverativ Inc.NamePositionCityBIOGEN IDEC INC10% Owner CAMBRIDGERichard  BrudnickEVP, Business Development CAMBRIDGELucia  CelonaEVP, HR & Corp Commun. Officer CAMBRIDGEJohn  CoxChief Executive Officer WESTONAlexander J  DennerDirector GREENWICHAndrea  DiFabioEVP, Chief Legal Officer CAMBRIDGEDiantha  DuvallChief Accounting Officer WALTHAMGeno J  GermanoDirector MADISONJohn  GreeneEVP, CFO and Treasurer LONDON, ENGLANDTimothy J.R.  HarrisEVP, R & D WALTHAMLOUIS J  PAGLIADirector NEW HAVENBrian S  PosnerDirector NEW YORKAnna  ProtopapasDirector CAMBRIDGECoelho Rogerio  VivaldiEVP, Chief Global Therapeutics CAMBRIDGE












 
















Coelho Rogerio Vivaldi - Spark Therapeutics Insider Transactions | TipRanks   





Go ProLogin / Sign Up Follow✓Get Real Time TransactionsInsider DetailsCoelho Rogerio VivaldiSpark Therapeutics (ONCE)CCORanked #18,996 out of 33,852 Insiders on TipRanksCoelho Rogerio Vivaldi's PerformanceProfitable Transactions1 out of 3 profitable transactionsAverage  Return-7.1%Average return per transactionEach transaction is measured over a 1 Year3 Months1 Month period, and compared to No BenchmarkS&P 500Sector.How are Insiders Ranked? Insider Holdings 79.8% Spark Therapeutics (ONCE) 20.2% Minerva Neurosciences (NERV)$2MSee the Top Stocks by Insiders > Insider RolesSpark Therapeutics (ONCE): CCOMinerva Neurosciences (NERV): President & CEO, DirectorSee the Top 25 Corporate Insiders > Most Profitable Insider TradeStock: Spark Therapeutics (ONCE)Transaction Type: Informative BuyDates: Feb 06, 2015 - Feb 06, 2016Gain: +9.9%See the Latest Stocks Traded by Insiders > Coelho Rogerio Vivaldi's Trading Historybased on Form 4 Follow✓Get Real Time TransactionsCompany NameInsider PositionHolding ValueLast TransactionLast Transaction  AmountLast Transaction DateONCESpark TherapeuticsCCO$1,654,373Uninformative Sell$371,224Jul 19, 2016NERVMinerva NeurosciencesPresident & CEO, Director$417,591Informative Buy$250,002Jul 09, 2014See All Insider Trading from Today >You May Also LikeMeet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.Related LinksHow can I benefit from Insider Trading? >See the Top 25 Corporate Insiders >Go to Hot Stocks by Insiders >Find which stocks Insiders traded today >Become a TipRanks MemberGet the best Investing Tips & Hacks straight to your emailFree MembershipSubmitInsider Trading Daily NewsletterProfessional day-trading strategy based on predictive insider transactionsAnnual Return: +85.42%Learn More >Powered by





























News on Rogério Vivaldi Coehlo


























































                      NEWS HOME
                    

Advertising
Board and Executive Moves
Energy
Health Care
Hedge Funds
M & A
Private Equity
Technology















                                Person                            


                                    Rogério Vivaldi Coehlo                                    ▼





                                Topic                            


                                    All Topics                                    ▼








Organizations

                                Find news about organizations
                            





Alumni

                                Find news on alumni of any org
                            





Industries

                                Find news on a particular market
                            





Your Contacts

                                Find news on your contacts
                            








Sign up for free daily alerts on this feed:











By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions


















Follow




                            Change Feed
                        


Rogério Vivaldi Coehlo











Biogen Announces Additional Members of Management Team of Hemophilia Spin-off Company Bioverativ


                                November 15, 2016                                 • 
                                Business Wire                            


                                  ... development and commercialization of treatments for hemophilia and other blood disorders. Rogerio Vivaldi, M.D., will serve as executive vice president and chief global therapeutic operations ...
                                









Rogerio Coelho Vivaldi sold $2.62M worth of shares in Spark Therapeutics, Inc. in October 2015


                                November 8, 2015                                 • 
                                RelSci Data Update                            










Headliner: Spark CCO maps gene therapy vision


                                October 26, 2015                                 • 
                                Medical Marketing & Media (MMM)                            


                                  ... Speaking with Dr. Rogerio Vivaldi, it's easy to forget that he's in the middle of one ...
                                









?Minerva Neurosciences raises $31M in stock, warrant offerings


                                March 24, 2015                                 • 
                                Boston Business Journal                            


                                  ... moved from Cambridge to Waltham and replaced its CEO, former Genzyme executive Rogerio Vivaldi, with Luthringe r a few months after its public offering last ...
                                









People in the News


                                January 12, 2015                                 • 
                                Philadelphia Inquirer                            


                                  ... L.L.C., a Philadelphia company developing gene-based medicines for debilitating diseases, has named Rogerio Vivaldi chief commercial officer. Vivaldi, former head of rare diseases at Genzyme, ...
                                









Spark Therapeutics Appoints Rare Disease Pioneer Dr. Rogerio Vivaldi as Chief Commercial Officer: Former head of rare diseases at Genzyme brings a 20-year track record of delivering successful, innovative products to patients throughout the world


                                December 16, 2014                                 • 
                                PR Newswire                            


                                  ... Spark Therapeutics Appoints Rare Disease Pioneer Dr. Rogerio Vivaldi as Chief Commercial Officer: Former head of rare diseases at Genzyme ...
                                









Former Genzyme executive Vivaldi replaced as CEO of Minerva (Video)


                                November 25, 2014                                 • 
                                Boston Business Journal                            


                                  ... Former Genzyme executive Vivaldi replaced as CEO of Minerva (Video) Minerva Neurosciences, a biotech focused on ...
                                









Rare disease drug pioneer at Genzyme turns focus to schizophrenia (Video)


                                September 22, 2014                                 • 
                                Boston Business Journal                            


                                  ... disease drug pioneer at Genzyme turns focus to schizophrenia (Video) Last year, Rogerio Vivaldi's career made an about face in more ways than one. After ...
                                









Mark S. Levine Joins Minerva Neurosciences as VP and General Counsel


                                August 18, 2014                                 • 
                                PR Newswire                            


                                  ... in planning and executing our business strategy in the years ahead," said Mr. Vivaldi. About Minerva Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused ...
                                









Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer


                                July 14, 2014                                 • 
                                PR Newswire                            


                                  ... an ideal addition to the senior team at Minerva Neurosciences," said Rogerio Vivaldi, MD, MBA, Minerva president and CEO. About Minerva Minerva Neurosciences, Inc. is ...
                                









Minerva Neurosciences To Ring NASDAQ Stock Market Closing Bell On July 7, 2014


                                July 7, 2014                                 • 
                                PR Newswire                            


                                  ... new therapies to treat neuropsychiatric diseases and disorders, today announced that Rogerio Vivaldi, MD, MBA, Minerva president and CEO, along with additional members of the ...
                                









Minerva completes its IPO, but the price is much less than expected


                                July 1, 2014                                 • 
                                Boston Business Journal                            


                                  ... company hired the former vice president of rare diseases at Genzyme Corp., Rogerio Vivaldi, as its chief executive. And in March, the company moved its ...
                                









Minerva Neuroscience raises $96M in initial stock offering


                                June 26, 2014                                 • 
                                Boston Business Journal                            


                                  ... Chinese biotech firm, Sonkei Pharmaceuticals, and moved to Kendall Square after naming Rogerio Vivaldi, former vice president of rare diseases at Genzyme, as its CEO, ...
                                









In record year, Minvera, Syndax aim for IPOs next week


                                June 20, 2014                                 • 
                                Boston Business Journal                            


                                  ... it named the former vice president of rare diseases at Genzyme Corp., Rogerio Vivaldi, as its CEO. It also named Marc Beer, CEO of Aegerion ...
                                









Spark Therapeutics Appoints Industry Leaders Lars Ekman and Vin Milano to Board of Directors


                                June 16, 2014                                 • 
                                PR Newswire                            


                                  ... including Elliott Sigal, former director, EVP and CSO of Bristol-Myers Squibb, and Rogério Vivaldi, former head of the rare diseases business unit at Genzyme, a ...
                                









Minerva Neurosciences Launches New Web Site Following Transfer Of Corporate Headquarters To Cambridge And Expansion Of Leadership Team


                                March 5, 2014                                 • 
                                PR Newswire                            


                                  ... establishment of a new corporate headquarters follows the recent appointment of Rogerio Vivaldi, MD, MBA, as the new president and CEO, and Marc Beer as ...
                                









Spark Therapeutics Appoints Industry Leader Dr. Elliott Sigal, Former Executive Vice President and Chief Scientific Officer of Bristol-Myers Squibb, to Board of Directors.


                                February 11, 2014                                 • 
                                PR Newswire                            


                                  ... patients who are suffering from serious genetic conditions." Spark recently appointed Rogerio Vivaldi, M.D., M.B.A., former senior vice president and Head of Rare Diseases at ...
                                









Spark Therapeutics Names Dr. Rogerio Vivaldi to Board of Directors


                                January 21, 2014                                 • 
                                PR Newswire                            


                                  ... He received his medical degree from Universidade do Rio de Janeiro (UNIRIO) Medical School, and completed his residency in endocrinology at Universidade do Estado do ...
                                









Genzyme Convenes 1st International Gaucher Conference on Bone Disease


                                July 1, 2013                                 • 
                                Business Wire                            


                                  ... in patients with Gaucher disease," said Genzyme's Head of Rare Diseases, Rogerio Vivaldi, MD. "This meeting brings together in Rio international experts from across a ...
                                









Genzyme Convenes 14th Annual North American Lysosomal Storage Disorder Registries Meeting


                                June 12, 2013                                 • 
                                Business Wire                            


                                  ... of patients around the world," said Genzyme's Head of Rare Diseases Rogerio Vivaldi, MD. "As we look forward to the next twenty years, the need ...
                                









Genzyme Convenes 13th European Fabry Disease Roundtable


                                April 18, 2013                                 • 
                                Business Wire                            


                                  ... our understanding of this disease," said Genzyme's Head of Rare Diseases Rogerio Vivaldi, MD. "As we continue to better understand the optimal way to care ...
                                









Genzyme's Head of Rare Diseases Honored by the Genetic Disease Foundation.


                                March 4, 2013                                 • 
                                Business Wire                            


                                  ... Genzyme's Head of Rare Diseases Honored by the Genetic Disease Foundation; Rogerio Vivaldi MD Receives Industry Person of the Year Genzyme , a Sanofi company ...
                                









Genzyme's Head of Rare Diseases Honored by the Genetic Disease Foundation


                                March 4, 2013                                 • 
                                Business Wire                            


                                  ... and NYSE: SNY), today announced that Genzyme's Head of Rare Diseases, Rogerio Vivaldi, MD, has been honored as the Genetic Disease Foundation's Industry Person of ...
                                









2013 BIO International Convention to Host Orphan Disease Forum. DL WASHINGTON


                                February 28, 2013                                 • 
                                Business Wire                            










2013 BIO International Convention to Host Orphan Disease Forum


                                February 28, 2013                                 • 
                                Business Wire                            








Related News Feeds






Bioverativ, Inc.







Biotechnology







Board and Executive Moves in Biotechnology







Alumni of Federal University of Rio de Janeiro

























































































































Email







LinkedIn







Facebook







Google+







Tweet







Reddit





Permalink



 






Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!


Start My Free Trial  ➤










 Industry:




 Select a Topic:



 Keyword:



Go  ➤









 Find an Organization:






 Select a Topic:




 Keyword:




Go  ➤









 Find a Person:






 Select a Topic:




 Keyword:




Go  ➤









 Name of a School:







 Or Name of an Organization:









 Select a Topic:




 Keyword:




Go  ➤








Thank you. You are now subscribed.Please wait for the page to refresh...










You are now subscribed to this feed.










You have unsubscribed to this feed.










Thank you. You can now subscribe to more RelSci news feeds.










 To subscribe to more than one feed, please enter a password.




 Please confirm your password



Go  ➤








You've found a premium RelSci Pro feature!



Follow News On Your Contacts

Upgrade to RelSci Pro now to easily sync your contacts and stay in the know on the news about the people important to you.


Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.



Not Now








You've found a premium RelSci Pro feature!



Search News On Keywords

Curate your news even further with the ability to filter feeds based on specific keywords mentioned in the articles.


Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.



Not Now













Industries

                        Find news on a particular market
                    





People

                        Find news about people
                    





Organizations

                        Find news about organizations
                    





Alumni

                        Find news on alumni of any org
                    





Your Contacts

                        Find news on your contacts
                    












                Free Daily Alerts
            


                Sign up for free daily alerts on this feed
            




Sign Up ➤

                    By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions




                Already have an account?  Click here to login.















Are you a RelSci Pro Subscriber?

Login to RelSci Pro 
                        ➤


Not a Pro Subscriber? Log in here to manage your alerts









 Keep me signed in.
        

Login  ➤



        Forgot your Password?
    

























 I have read the LexisNexis terms & conditions




Sign Me Up  ➤
















VIVALDI COELHO ROGERIO Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      VIVALDI COELHO ROGERIO
                    

•   WALTHAM, MA
                      
How do I update this listing?




                                             Vivaldi Coelho Rogerio is based out of Waltham.   
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from VIVALDI COELHO ROGERIO, enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




vivaldi coelho rogerio


225 SECOND AVENUE

WALTHAM
MA
                                                        
                                                    02451









Recent SEC Filings




4/A filed on 03/27/2017
4 filed on 02/16/2017
3 filed on 12/22/2016
4 filed on 07/19/2016
4 filed on 04/22/2016
4 filed on 01/07/2016
4 filed on 10/14/2015
4 filed on 10/09/2015
4 filed on 02/06/2015
3 filed on 01/29/2015
















Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free

















